PURPOSE: Anticoagulation therapy aims to improve the outcome of critically ill patients with severe COVID-19-associated pneumonia. Activated partial thromboplastin time (aPTT) is commonly used to maintain the target therapeutic range of continuous infusion of unfractionated heparin (UFH). The UFH infusion efficacy can be evaluated by determining the time in therapeutic range (TTR) using a modified Rosendaal method. The present study's primary aim was to evaluate TTR based on the aPTT in critically ill patients with severe forms of COVID-19 pneumonia and its influence on survival. The secondary aim was to evaluate the time spent above (TATR) and below the therapeutic range (TBTR). PATIENTS AND METHODS: We performed a retrospective analysis of critically ill patients with COVID-19-associated pneumonia. All patients received a continuous infusion of UFH from the 2nd to 8th day since admission to the ICU. TTR, TATR, and TBTR were calculated using the modified Rosendaal method, and survival days were analyzed by regression (censored after 60 days). RESULTS: Of 103 patients, the median TTR was 49% (IQR 38-63%), TATR 11% (IQR 5-20%), and TBTR 33% (IQR 22-51%). The regression analysis indicated a positive impact of higher TTR and TATR on the number of survival days [β=0.598 (p=0.0367) and β=1.032 (p=0.0208), respectively] and a negative impact of higher TBTR [β=-0.681 (p=0.0033)] on the number of survival days. CONCLUSION: Higher TTR and TATR were associated with better survival of critically ill patients with a severe course of COVID-19-associated pneumonia. Higher TBTR was associated with worse survival in these patients.

Department of Anesthesiology and Intensive Care Medicine University Hospital Ostrava Czech Republic

Department of Infectious Diseases University Hospital Ostrava Ostrava Czech Republic

Department of Intensive Medicine Emergency Medicine and Forensic Studies Faculty of Medicine University of Ostrava Ostrava Czech Republic

Institute for Research and Applications of Fuzzy Modeling CE IT4Innovations University of Ostrava Ostrava Czech Republic

Institute of Laboratory Medicine University Hospital Ostrava Ostrava Czech Republic

Institute of Physiology and Pathophysiology Faculty of Medicine University of Ostrava Ostrava Czech Republic

See more in PubMed

Conway EM, Mackman N, Warren RQ, et al. Understanding COVID-19-associated coagulopathy. Nat Rev Immunol. 2022;22(10):639–649. doi:10.1038/s41577-022-00762-9 PubMed DOI PMC

Lorini FL, Di Matteo M, Gritti P, et al. Coagulopathy and COVID-19. Eur Hear J Suppl. 2021:23(Supplement_E):E95–E98. doi:10.1093/eurheartj/suab100. PubMed DOI PMC

Xiang G, Hao S, Fu C, et al. The effect of coagulation factors in 2019 novel coronavirus patients. Medicine. 2021;100(7):e24537. doi:10.1097/MD.0000000000024537 PubMed DOI PMC

COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health; 2024. Available from: https://www.covid19treatmentguidelines.nih.gov/. Accessed September 04, 2024. PubMed

Thachil J. The versatile heparin in COVID‐19. J Thromb Haemost. 2020;18(5):1020–1022. doi:10.1111/jth.14821 PubMed DOI PMC

Gozzo L, Viale P, Longo L, Vitale DC, Drago F. The Potential Role of Heparin in Patients With COVID-19: beyond the Anticoagulant Effect. A Review. Front Pharmacol. 2020;11:1307. doi:10.3389/fphar.2020.01307 PubMed DOI PMC

Morales Castro D, Dresser L, Granton J, Fan E. Pharmacokinetic Alterations Associated with Critical Illness. Clin Pharmacokinet. 2023;62(2):209–220. doi:10.1007/s40262-023-01213-x PubMed DOI PMC

Zufferey PJ, Dupont A, Lanoiselée J, et al. Pharmacokinetics of enoxaparin in COVID-19 critically ill patients. Thromb Res. 2021;205:120–127. doi:10.1016/j.thromres.2021.07.010 PubMed DOI PMC

Tree JA, Turnbull JE, Buttigieg KR, et al. Unfractionated heparin inhibits live wild type SARS‐CoV‐2 cell infectivity at therapeutically relevant concentrations. Br J Pharmacol. 2021;178(3):626–635. doi:10.1111/bph.15304 PubMed DOI PMC

Ting C, Sylvester KW, Schurr JW. Time in the Therapeutic Range for Assessing Anticoagulation Quality in Patients Receiving Continuous Unfractionated Heparin. Clin Appl Thromb. 2018;24(9_suppl):178S–181S. doi:10.1177/1076029618798944 PubMed DOI PMC

Reiffel J. Time in the Therapeutic Range (TTR): an Overly Simplified Conundrum. J Innov Card Rhythm Manag. 2017;8(3):2643–2646. doi:10.19102/icrm.2017.080302 PubMed DOI PMC

R Core Team. R: A Language and Environment for Statistical computing. 2013.

Gallagher A, Setakis E, Plumb J, Clemens A, van Staa TP. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost. 2011;106(11):968–977. doi:10.1160/TH11-05-0353 PubMed DOI

Loeliger EA. Laboratory Control, Optimal Therapeutic Ranges and Therapeutic Quality Control in Oral Anticoagulation. Acta Haematol. 1985;74(3):125–131. doi:10.1159/000206187 PubMed DOI

Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E, A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69(3):236–239.:. PubMed

Knaus WA, Draper EA, Wagner DP, Zimmerman JE, APACHE II: a severity of disease classification system. Crit Care Med. 1985;13(10):818–829. PubMed

Cauchie P, Piagnerelli M. What Do We Know about Thromboprophylaxis and Its Monitoring in Critically Ill Patients? Biomedicines. 2021;9(8):864. doi:10.3390/biomedicines9080864 PubMed DOI PMC

van Roessel S, Middeldorp S, Cheung YW, Zwinderman AH, de Pont ACJM. Accuracy of aPTT monitoring in critically ill patients treated with unfractionated heparin. Neth J Med. 2014;72(6):305–310. PubMed

Uprichard J, Manning RA, Laffan MA. Monitoring heparin anticoagulation in the acute phase response. Br J Haematol. 2010;149(4):613–619. doi:10.1111/j.1365-2141.2010.08129.x PubMed DOI

Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety. Chest. 2001;119(1):64S–94S. doi:10.1378/chest.119.1_suppl.64S PubMed DOI

Toulon P, Smahi M, De Pooter N. APTT therapeutic range for monitoring unfractionated heparin therapy. Significant impact of the anti‐Xa reagent used for correlation. J Thromb Haemost. 2021;19(8):2002–2006. doi:10.1111/jth.15264 PubMed DOI